Nancy Valente Biography and Net Worth

Executive Vice President & Chief Development Officer of Xencor

Dr. Valente is responsible for leading Xencor's clinical and medical strategy and execution. Prior to Xencor, she most recently served as a senior vice president at Genentech, a member of the Roche Group, and as its global head and co-lead of global product development of its oncology and hematology therapeutic area. In this role at Genentech, Dr. Valente was responsible for strategic planning, clinical development and collaboration activities in the areas of oncology and hematology product development, playing a critical role in the development and approvals of new therapies for patients with serious illnesses, including GAZYVA®, VENCLEXTA®, POLIVY® and HEMLIBRA®. Dr. Valente has held various positions with increasing responsibilities at Genentech and then at Roche after Genentech was acquired by Roche, including vice president for global product development for oncology, hematology franchise and senior group medical director, leader for hematology development. Before Genentech, she served in senior-level positions at Anosys, Inc. and Coulter Pharmaceutical, Inc., and earlier in her career, she held academic positions at the University of California, San Francisco (UCSF). Dr. Valente received her M.D. from the University of Missouri and completed her internal medicine training at Oregon Health & Science University, followed by fellowships in hematology at Stanford University and oncology at UCSF.

What is Nancy Valente's net worth?: The estimated net worth of Nancy Valente is at least $891.93 thousand as of May 2nd, 2025. Dr. Valente owns 49,169 shares of Xencor stock worth more than $891,926 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Valente may own. Additionally, Dr. Valente receives a salary of $797,680.00 as Executive Vice President & Chief Development Officer at Xencor. Learn More about Nancy Valente's net worth.
How old is Nancy Valente?: Dr. Valente is currently 65 years old. There are 4 older executives and no younger executives at Xencor. Learn More on Nancy Valente's age.
What is Nancy Valente's salary?: As the Executive Vice President & Chief Development Officer of Xencor, Inc., Dr. Valente earns $797,680.00 per year. The highest earning executive at Xencor is Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, President & Director, who commands a salary of $1,070,000.00 per year. Learn More on Nancy Valente's salary.
How do I contact Nancy Valente?: The corporate mailing address for Dr. Valente and other Xencor executives is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. Xencor can also be reached via phone at (626) 305-5900 and via email at [email protected]. Learn More on Nancy Valente's contact information.
Has Nancy Valente been buying or selling shares of Xencor?: Nancy Valente has not been actively trading shares of Xencor within the last three months. Most recently, Nancy Valente sold 4,616 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a transaction totalling $50,914.48. Following the completion of the sale, the executive vice president now directly owns 49,169 shares of the company's stock, valued at $542,334.07. Learn More on Nancy Valente's trading history.
Who are Xencor's active insiders?: Xencor's insider roster includes Bassil Dahiyat (CEO), John Desjarlais (Executive Vice President, Research & Chief Scientific Officer), Celia Eckert (Senior Vice President, General Counsel and Corporate Secretary), Ellen Feigal (Director), Kurt Gustafson (Director), Alan Montgomery (Director), Richard Ranieri (Director), Nancy Valente (Executive Vice President & Chief Development Officer), and Allen Yang (CMO). Learn More on Xencor's active insiders.
Are insiders buying or selling shares of Xencor?: In the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 15,810 shares worth more than $154,123.16. The most recent insider tranaction occured on June, 16th when Director Alan Bruce Montgomery sold 2,215 shares worth more than $20,422.30. Insiders at Xencor own 4.8% of the company. Learn More about insider trades at Xencor.
Information on this page was last updated on 6/16/2025.

Nancy Valente Insider Trading History at Xencor

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/2/2025	Sell	4,616	$11.03	$50,914.48	49,169

Nancy Valente Buying and Selling Activity at Xencor

Xencor Company Overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Today's Range

Now: $18.14

$17.02

$18.68

50 Day Range

MA: $14.36

$11.55

$18.14

2 Week Range

Now: $18.14

$6.92

$26.59

Volume

950,883 shs

Average Volume

728,373 shs

Market Capitalization

$1.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Nancy Valente Biography and Net Worth

What is Nancy Valente's net worth?

How old is Nancy Valente?

What is Nancy Valente's salary?

How do I contact Nancy Valente?

Has Nancy Valente been buying or selling shares of Xencor?

Who are Xencor's active insiders?

Are insiders buying or selling shares of Xencor?